 Shares of Vaxcyte Inc. soared 22 in their trading debut Friday, after the companys IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to sell just 14 million. The company raised 249.6 million. The shares are trading on Nasdaq later Friday under the ticker symbol PCVX. BofA Securities, Jefferies and Evercore ISI were lead underwriters on the deal with Cantor and Needham acting as co-managers. We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, says the prospectus. Proceeds of the deal will be used top fund clinical development and for general corporate purposes. 